

| | | | | |
|---|----------------------|---------------------|------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10524963 | |
| | Filing Date | | 2005-02-18 | |
| | First Named Inventor | David William Tonge | | |
| | Art Unit | 1614 | | |
| | Examiner Name | Leslie A. Royds | | |
| Attorney Docket Number | | 100815-1P US | | |

| U.S. PATENTS | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

| U.S. PATENT APPLICATION PUBLICATIONS | | | | | | Remove |
|--------------------------------------|---------|--------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

| FOREIGN PATENT DOCUMENTS | | | | | | | Remove | |
|--------------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|--------------------------|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² j | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | 1 | | | | | | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

| NON-PATENT LITERATURE DOCUMENTS | | | Remove |
|---------------------------------|---------|---|----------------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
| | | | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

/Leslie A. Royds/ (05/14/2009)

Receipt date: 01/30/2009

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------------|----------------------|
| Application Number | 10524963 | 10524963 - GAU: 1614 |
| Filing Date | 2005-02-18 | |
| First Named Inventor | David William Tonge | |
| Art Unit | 1614 | |
| Examiner Name | Leslie A. Royds | |
| Attorney Docket Number | 100815-1P US | |

| | | |
|----|--|--------------------------|
| 1 | BRADBURY, Robert, H et al, "New Non-peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides". J Med Chem. 14 May 1997. 396-1004. 40. | <input type="checkbox"/> |
| 2 | BROOKS N. et al, "ZD4054 – a specific endothelin-A receptor antagonist providing hope for treatment of HRPc", 4th PacRim Breast and Prostate Cancer Meeting. British Columbia, Canada, 12–16 August 2008. abstract | <input type="checkbox"/> |
| 3 | CARDUCCI M.A. et al, "Targeting bone metastasis in prostate cancer with endothelin receptor antagonists", Clin Cancer Res, 2006, 6296s–6300s, 12. | <input type="checkbox"/> |
| 4 | CARDUCCI, M.A. et al, "The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Delays Clinical Progression in Hormone Refractory Prostate Cancer: a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial", ASCO Abstracts 2001. | <input type="checkbox"/> |
| 5 | CARRAGHER N. et al "Application of 3-dimensional (3D) in vitro invasion assays demonstrate anti-invasive activity of the specific endothelin-A (ETA) receptor-antagonist ZD4054 when combined with the novel Src/Abl inhibitor AZD0530" NCRI. Birmingham, UK, 5–8 October 2008; abst B77. | <input type="checkbox"/> |
| 6 | CHIAO, J.W. et al, "Endothelin-1 from Prostate Cancer Cells is enhanced by bone contact which blocks osteoclastic bone resorption", British Journal of Cancer, 2000, 360-365, 83(3). | <input type="checkbox"/> |
| 7 | CHIRGWIN, J.M. et al, "Tumor-bone cellular interactions in skeletal metastases", J Musculoskel Neuron Interact, 2004, 308-318, 4(3). | <input type="checkbox"/> |
| 8 | CLARKSON-JONES J. et al, "Metabolism of [14C]-ZD4054 in healthy volunteers", Drug Metab Rev, 2008, 206, 40 (Suppl 3) (Abstract 283). | <input type="checkbox"/> |
| 9 | CLARKSON-JONES J. et al, "Metabolism of [14C]-ZD4054 in healthy volunteers", poster, ISSX – 15th North American Regional Meeting, San Diego, USA, 12–16 October 2008 | <input type="checkbox"/> |
| 10 | CURWEN J et al, "The impact of ZD4054, a specific endothelin-A receptor antagonist, on tumor blood supply, invasion and the bone microenvironment" Mol Cancer Ther, 2007;6(12) Suppl II:abst A272. | <input type="checkbox"/> |
| 11 | CURWEN J et al, "The impact of ZD4054, a specific endothelin-A receptor antagonist, on tumor blood supply, invasion and the bone microenvironment", AACR-NCI-EORTC, San Francisco, USA, 22–26 October 2007. Poster. | <input type="checkbox"/> |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

/Leslie A. Royds/ (05/14/2009)

| | | |
|------------------------|---------------------|----------------------|
| Application Number | 10524963 | 10524963 - GAU: 1614 |
| Filing Date | 2005-02-18 | |
| First Named Inventor | David William Tonge | |
| Art Unit | 1614 | |
| Examiner Name | Leslie A. Royds | |
| Attorney Docket Number | 100815-1P US | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|----|--|--------------------------|
| 12 | CURWEN, J. et al, "The specific endothelin A receptor antagonist ZD4054 reduces tumour-induced angiogenesis in a preclinical model", 10th International Conference on Endothelin (ET-10). Bergamo, Italy, 16-19 September 2007; oral presentation | <input type="checkbox"/> |
| 13 | CURWEN, J. et al, "The specific endothelin A receptor antagonist ZD4054 reduces tumour-induced angiogenesis in a preclinical model", 10th International Conference on Endothelin (ET-10). Bergamo, Italy, 16-19 September 2007; poster | <input type="checkbox"/> |
| 14 | DAWSON N. et al, "Impact of the specific endothelin-A (ETA) receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial", Current Treat Options Oncol 2008; 105-107, 9(Suppl 1). | <input type="checkbox"/> |
| 15 | DAWSON N. et al, "Impact of the specific endothelin-A (ETA) receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial", oral presentation, Chemotherapy Foundation Symposium, New York, USA, 4-7 November 2008 | <input type="checkbox"/> |
| 16 | DAWSON N. et al, "Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial", ASCO GU Congress, San Francisco, USA 14-16 February 2008, Genitourinary Cancers Symposium Proceedings 2008; abst 7. | <input type="checkbox"/> |
| 17 | DAWSON N. et al, "Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial", ASCO GU Congress, San Francisco, USA 14-16 February 2008, poster. | <input type="checkbox"/> |
| 18 | DINGEMANSE, J. et al, "Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects", Br J Clin Pharmacol, 28 Apr 2002, 355-362, 53. | <input type="checkbox"/> |
| 19 | FIZAZI K et al, "The Effects of Endothelin-1 and Abt-627, and Endothelin-1 Antagonist, in an in Vitro Model of Bone Metastases from Prostate Cancer", Asco Abstracts 2001. | <input type="checkbox"/> |
| 20 | GODARA G. et al, "Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer", UROLOGY, 2007, 209-215, Vol 70(1). | <input type="checkbox"/> |
| 21 | GODARA G. et al, "Role of Endothelin Axis in progression to Aggressive Phenotype of Prostate Adenocarcinoma", The Prostate, 2005, 27-34, 65. | <input type="checkbox"/> |
| 22 | GROSS-GOUPIL M. et al, "Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer", European Urology Supplements, 2009, 114-119, 8. | <input type="checkbox"/> |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

/Leslie A. Royds/ (05/14/2009)

Receipt date: 01/30/2009

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------------|----------------------|
| Application Number | 10524963 | 10524963 - GAU: 1614 |
| Filing Date | 2005-02-18 | |
| First Named Inventor | David William Tonge | |
| Art Unit | 1614 | |
| Examiner Name | Leslie A. Royds | |
| Attorney Docket Number | 100815-1P US | |

| | | |
|----|---|--------------------------|
| 23 | GROWCOTT J. et al "ZD4054 – A small-molecule, specific endothelin-A receptor antagonist: providing hope for patients with hormone-resistant prostate cancer", AZ-Manchester Cancer Research Centre Showcase. Manchester, UK, 22 September 2008. | <input type="checkbox"/> |
| 24 | GROWCOTT J. et al, "Anti-invasive activity of the specific endothelin-A receptor (ETAR) antagonist, ZD4054, in A673 rhabdomyosarcoma cells", 10th International Conference on Endothelin (ET-10). Bergamo, Italy, 16–19 September 2007. Poster. | <input type="checkbox"/> |
| 25 | GROWCOTT J. et al, "Anti-invasive activity of the specific endothelin-A receptor (ETAR) antagonist, ZD4054, in A673 rhabdomyosarcoma cells", 10th International Conference on Endothelin (ET-10). Bergamo, Italy, 16–19 September 2007. Oral Presentation. | <input type="checkbox"/> |
| 26 | GROWCOTT J.W. et al, "Phenotypic in vitro differentiation of the specific endothelin A receptor antagonist, ZD4054, from the selective endothelin antagonist, atrasentan", Mol Cancer Ther, 2007; 6(12) Suppl II:abst B269. | <input type="checkbox"/> |
| 27 | GROWCOTT J.W. et al, "Phenotypic in vitro differentiation of the specific endothelin A receptor antagonist, ZD4054, from the selective endothelin antagonist, atrasentan", AACR-NCI-EORTC, San Francisco, USA, 22–26 October 2007. Poster. | <input type="checkbox"/> |
| 28 | GROWCOTT, J.W., "Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054", Anti-Cancer Drugs 2009, 00:000–000. | <input type="checkbox"/> |
| 29 | GUISE T. et al, "Endothelin A Receptor Blockade Inhibits Osteoblastic Metastases", Asco Abstracts 2001. | <input type="checkbox"/> |
| 30 | HICKINSON D.M. et al, "Enhanced in vitro anti-invasive activity in A673 rhabdomyosarcoma cells of the specific endothelin-A receptor (ETA) antagonist ZD4054 when combined with the novel Src inhibitor AZD0530", Proc Am Assoc Cancer Res, 2008, 49 :abst 1487. | <input type="checkbox"/> |
| 31 | HICKINSON D.M. et al, "Enhanced in vitro anti-invasive activity in A673 rhabdomyosarcoma cells of the specific endothelin-A receptor (ETA) antagonist ZD4054 when combined with the novel Src inhibitor AZD0530", AACR Annual Meeting, San Diego, CA, USA, 12–16 April 2008. Poster | <input type="checkbox"/> |
| 32 | ISHERWOOD B. et al "Enhanced in vitro anti-invasive activity in A673 rhabdomyosarcoma cells of the specific endothelin-A (ETA) antagonist ZD4054 when combined with the novel Src/Abl inhibitor AZD0530" NCRI. Birmingham, UK, 5–8 October 2008, poster. | <input type="checkbox"/> |
| 33 | JAMES N, et al, "The potent, specific endothelin A receptor antagonist ZD4054 improves overall survival in patients with pain-free or mildly symptomatic M1 hormone-resistant prostate cancer" 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain, 2–4 November 2007,abst O2. | <input type="checkbox"/> |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

/Leslie A. Royds/ (05/14/2009)

| | | |
|------------------------|---------------------|----------------------|
| Application Number | 10524963 | 10524963 - GAU: 1614 |
| Filing Date | 2005-02-18 | |
| First Named Inventor | David William Tonge | |
| Art Unit | 1614 | |
| Examiner Name | Leslie A. Royds | |
| Attorney Docket Number | 100815-1P US | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|----|--|--------------------------|
| 34 | JAMES N. "New clinical data for the specific ETA receptor antagonist ZD4054", EAU 2008 Milan Italy, 26-29 March 2008. Oral presentation. | <input type="checkbox"/> |
| 35 | JAMES N. et al, "The effect of ZD4054 on bone metastases in patients with M1 hormone-resistant prostate cancer as assessed by radionuclide bone scans", 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain, 2-4 November 2007; abst P10. | <input type="checkbox"/> |
| 36 | JAMES N. et al, "The effect of ZD4054 on bone metastases in patients with M1 hormone-resistant prostate cancer as assessed by radionuclide bone scans", 1st European Multidisciplinary Meeting on Urological Cancers. Barcelona, Spain, 2-4 November 2007. Poster. | <input type="checkbox"/> |
| 37 | James N.D. et al, "ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases" ECCO 14, Barcelona, Spain, 23-27 September 2007. Oral Presentation. | <input type="checkbox"/> |
| 38 | JAMES, N.D. et al, "Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial" Eur Urol (2008), doi:10.1016/j.eururo.2008.11.002. | <input type="checkbox"/> |
| 39 | JAMES, N.D. et al, "ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases", European Journal of Cancer Supplements, 2007, abstract 3LB, Vol. 5, No. 6. | <input type="checkbox"/> |
| 40 | KENYON A. et al, "The mystery of the co-eluting peak"; DMDG meeting. Cambridge, UK, 17-19 September 2007. Poster. | <input type="checkbox"/> |
| 41 | KNIGHT L.J. et al, "Hypermethylation of endothelin receptor type B (EDNRB) is a frequent event in non-small cell lung cancer", Proc Am Assoc Cancer Res, 2007, 48: abst 1135. | <input type="checkbox"/> |
| 42 | KNIGHT L.J. et al, "Hypermethylation of endothelin receptor type B (EDNRB) is a frequent event in non-small cell lung cancer", AACR, Los Angeles, CA, USA, 14-18 April 2007. Poster | <input type="checkbox"/> |
| 43 | KNIGHT, L.J., "Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer", International Journal of Oncology, 2009, 465-471, 34. | <input type="checkbox"/> |
| 44 | KOPETZ, Scott E et al, "Endothelin-1 as a target for therapeutic intervention in prostate cancer", Investigational New Drugs, May 2002, 173-182, 20. | <input type="checkbox"/> |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

Receipt date: 01/30/2009

| | | |
|------------------------|---------------------|----------------------|
| Application Number | 10524963 | 10524963 - GAU: 1614 |
| Filing Date | 2005-02-18 | |
| First Named Inventor | David William Tonge | |
| Art Unit | 1614 | |
| Examiner Name | Leslie A. Royds | |
| Attorney Docket Number | 100815-1P US | |

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

| | | |
|----|--|--------------------------|
| 45 | MOHAMMAD K., et al, "Combined endothelin A receptor antagonist and bisphosphonate treatment more effectively reduces prostate cancer growth in bone than either alone", American Society for Bone and Mineral Research, 27th Annual Meeting, 2005; 1213a. | <input type="checkbox"/> |
| 46 | NELSON J.B.et al, "Endothelin-1 inhibits apoptosis in prostate cancer", Neoplasia 2005, 631-7, 7(7) (abstract). | <input type="checkbox"/> |
| 47 | NELSON J.B.et al, "The Endothelin Axis: Emerging Role In Cancer", Nature Reviews Cancer, 2003, 110-116, 3. | <input type="checkbox"/> |
| 48 | NELSON J.B.et al, "The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Reduces Skeletal Remodeling Activity in Men with Advance Refractory Prostate Cancer", Asco Abstracts 2001. | <input type="checkbox"/> |
| 49 | PAYNE H. et al, "Progression-free survival, overall survival and bone metastasis in a phase II trial of the specific endothelin a receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer", Cury congress. Barcelona, Spain, 31 January – 3 February 2008. oral presentation | <input type="checkbox"/> |
| 50 | PFLUG BR et al, "Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents", Mol Cancer Ther, 2007;6(12) Suppl II: abst A287. | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--------------------------------|-----------------|--|
| Examiner Signature | /Leslie A. Royds/ (05/14/2009) | Date Considered | |
|--------------------|--------------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)